Cantor Fitzgerald Initiates Coverage On Nuvectis Pharma with Overweight Rating
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiation
Cantor Fitzgerald analyst Pete Stavropoulos initiates coverage on Nuvectis Pharma (NASDAQ:NVCT) with a Overweight rating.
Cantor Fitzgerald analyst Pete Stavropoulos initiates coverage on Nuvectis Pharma (NASDAQ:NVCT) with a Overweight rating.